Entia Biosciences, Inc. (ERGO)
OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
At close: Jan 27, 2026

Entia Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
0.270.350.660.310.37
Revenue Growth (YoY)
-23.48%-47.14%108.53%-14.77%-8.45%
Cost of Revenue
0.090.130.250.130.11
Gross Profit
0.170.220.410.180.26
Selling, General & Admin
1.342.132.182.871.34
Operating Expenses
1.342.132.182.871.34
Operating Income
-1.17-1.92-1.77-2.68-1.08
Interest Expense
-0.08-0.17-0.44-0.14-0.26
Interest & Investment Income
---0.010
Other Non Operating Income (Expenses)
-0.01-0.040.01--
EBT Excluding Unusual Items
-1.26-2.12-2.2-2.82-1.34
Asset Writedown
-0.05-0.11-0.03-0.29-
Legal Settlements
-0.09----
Other Unusual Items
0-0.03-0.07-0.08
Pretax Income
-1.4-2.26-2.3-3.1-1.26
Net Income
-1.4-2.26-2.3-3.1-1.26
Preferred Dividends & Other Adjustments
---0.090.02
Net Income to Common
-1.4-2.26-2.3-3.19-1.29
Shares Outstanding (Basic)
2824987
Shares Outstanding (Diluted)
2824987
Shares Change (YoY)
15.84%157.24%25.34%3.22%16.62%
EPS (Basic)
-0.05-0.09-0.24-0.42-0.18
EPS (Diluted)
-0.05-0.09-0.24-0.42-0.18
Free Cash Flow
-0.72-0.54-0.68-0.82-0.33
Free Cash Flow Per Share
-0.03-0.02-0.07-0.11-0.04
Gross Margin
65.53%62.24%62.60%58.34%70.90%
Operating Margin
-439.75%-552.29%-269.82%-851.98%-292.65%
Profit Margin
-525.79%-651.48%-349.91%-1014.29%-348.13%
Free Cash Flow Margin
-269.38%-156.99%-104.35%-260.30%-89.84%
EBITDA
-1.15-1.88-1.73-2.65-1.06
EBITDA Margin
---264.02%--286.82%
D&A For EBITDA
0.020.030.040.040.02
EBIT
-1.17-1.92-1.77-2.68-1.08
EBIT Margin
---269.82%--292.65%
Advertising Expenses
0.090.130.130.170.04
Source: S&P Global Market Intelligence. Standard template. Financial Sources.